(AOF) – Guerbet announces a net profit of 1.3 million euros in the first half, compared to 3.3 million a year ago. The specialist in contrast products and solutions for medical imaging highlights that its turnover as of June 30 amounted to 378.6 million euros, an increase of 2% compared to the same period of 2022. ‘Ebitda reached 45.9 million euros compared to 50.5 million a year ago, with a margin rate of 12.1% compared to 13.6% in 2022. Guerbet confirms that it anticipates growth above 5% for 2023 of its turnover on a comparable basis and CER.
The restated EBITDA/CA margin rate is expected around 11%: The group expects a return in 2024 to a margin rate higher than that experienced in 2021 (14.4%).
“The contrast media market remains driven by structural growth in volumes accompanied by positive price effects,” states the group in its press release. “Business in the coming months will also benefit from the gradual ramp-up of Elucirem, and sustained growth in sales of Lipiodol. In terms of profitability, inflationary pressures (particularly iodine) will continue to rise. to be felt in the second half of 2023”.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
